Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Athira Pharma, Inc.

Athira Pharma to Participate in Upcoming June Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Participate in Upcoming May Investor Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Provides 2023 Pipeline Outlook
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present at Stifel 2022 Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.